Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. - Wikidata - wikimedia - TriplyDB

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

http://www.wikidata.org/entity/Q45184856

about

Systems vaccinology: probing humanity's diverse immune systems with vaccines.CpG oligodeoxynucleotides as mucosal adjuvants Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel Cutaneous immunization: an evolving paradigm in influenza vaccines Innate immune sensing and response to influenza.Translational research on influenza virus infection using a nonhuman primate model.NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02 TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.Potency of a vaccine prepared from A/swine/Hokkaido/2/1981 (H1N1) against A/Narita/1/2009 (H1N1) pandemic influenza virus strain Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis.The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway.Critical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine.A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity.Development of a novel, single-cycle replicable rift valley Fever vaccine.A micro-sterile inflammation array as an adjuvant for influenza vaccines.Immunological mechanisms of vaccination.Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males.Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination CD4 T cell epitope specificity determines follicular versus non-follicular helper differentiation in the polyclonal response to influenza infection or vaccination Autoimmune Variant PTPN22 C1858T Is Associated With Impaired Responses to Influenza Vaccination.RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine Immunity to viruses: learning from successful human vaccines Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.Molecular signatures of antibody responses derived from a systems biology study of five human vaccines Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design.Innate immunity and adjuvants.Inflammasomes in antiviral immunity: clues for influenza vaccine development.Challenges in mucosal vaccines for the control of infectious diseases.The Pseudorabies Virus Glycoprotein gE/gI Complex Suppresses Type I Interferon Production by Plasmacytoid Dendritic Cells.

P2860

Q27690799-606DA22A-BAAD-47DD-90F7-222CCEE6C480 Q28086998-85B1AF93-A750-49C4-88CE-C319444FAB5E Q28742787-8039F2B5-F2C0-47CD-A7A8-867CF6742220 Q30356053-94C040E8-629A-4A1D-9F38-A80619049B77 Q30358895-0B26B7AB-C90B-495C-8AA6-15CF81444BEF Q30365302-51CF664D-17C1-4B11-8B65-8B972D0B293C Q30383873-99DA8DDC-3DF4-4858-97F1-DFB734051231 Q30394706-093CC929-7B9A-48EE-BBAF-FF49A2424A47 Q30417157-998082F1-4421-4FC9-AF40-F579191B23D0 Q30419734-4A01AA38-C35E-4752-9FD9-89500282BA11 Q30426820-B6DBD092-6F21-4536-938B-92DF677FE157 Q30573156-C350E0AF-51B5-4BC2-AC54-E4F88EF613C9 Q33956662-40D9D04F-8E1E-486E-9836-9EFBED0D728B Q34313957-E139A3E7-5010-428F-9252-A624B5F5A0AD Q34653072-2D138697-1D2F-41ED-9F8D-ACB1F3530FF2 Q34669830-ADF496E5-FF79-412C-A2B0-6B738CEC1E19 Q34712969-322A6574-1B41-49D2-ABC8-36AC8299076B Q35106344-A5CC1D9B-DA53-4006-B2FB-D68A45939888 Q35126733-8C4C09B5-C037-49E0-ABE6-0D2F035CF329 Q35208463-7AF8BD12-5EBC-44C1-B60A-FA10480848D3 Q35659533-B1F3B9E2-DA35-4555-9307-DABCF63986D1 Q35762614-30EE6851-557A-47BE-8E29-5BDFFC16DE7A Q35853440-41CC3F9C-7DE4-45B7-BC48-8EAB67407D10 Q35885039-7450BAFA-358C-4754-91A2-2D5AE370F700 Q36035012-4D1A5ECA-A405-40F8-853B-2A9E971EB45B Q36069263-F64A03CE-A30D-4F0C-9406-2193800B9B0A Q36086253-1134B68F-3C1E-4F51-AF5E-8BEE4DF7D225 Q36752092-67486F72-162F-4443-AFA5-B353991A38C1 Q37027382-9B0FB840-6F2C-4996-91BB-714433118E69 Q37033053-EB2548DD-9B3C-49AB-AC23-102150ADF10E Q37061815-01B7121D-CAE5-4293-8AB8-0C3252D2FB1C Q37108439-4C50ACDB-E37E-4A08-B014-331BB7E29038 Q37530383-4C4BE395-63E2-49BE-8859-4ADDADB37476 Q37584248-17ED5A66-3448-4288-BF66-06A4138A94FF Q37625332-5C65FA2C-C90E-4E1E-9CB5-0254983DE38A Q37810600-E42C9552-63AC-4AE3-8469-9D6358B5D7A3 Q37926762-772BC1DE-C922-4FB3-A38F-FCA58282A4B8 Q38178692-C5EDE5FD-9650-4F29-AE59-23FB1EF012F1 Q38219010-00B7CC75-AE49-4470-BF18-93E7C395E1FF Q38998935-EB35C58A-9045-4A53-AC6E-107D886E3D1F

P2860

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

http://www.wikidata.org/entity/Q45184856

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@en

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@nl

type

label

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@en

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@nl

prefLabel

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@en

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@nl

P1433

Q45184856-36A379B7-50BE-45F3-8ED0-C2DE113DF90B

P1476

Q45184856-05DB5220-1826-440A-A602-902B5475DEFF

P2093

Q45184856-218416ED-2A62-4B6B-A193-2C5514DB4AA7

Q45184856-3AFAA49A-931B-4480-92A6-F5257502EBF7

Q45184856-66940375-7EA2-463D-9F4C-C54F427D238B

Q45184856-ABD6CACF-DCA9-444B-B234-4AAD20C288AA

Q45184856-ADA323FA-21D8-414C-A838-BD50BB14619D

Q45184856-C70EB85F-673C-4564-A595-18573E3CFDFB

P2860

Q45184856-0931936D-6FFA-49FD-8D98-C857009EAD5C

Q45184856-0AF8396B-0299-478A-900E-F83951B3E5E6

Q45184856-142B6569-CC30-449B-8392-742A1C1B3741

Q45184856-143770E4-FEA6-47FA-83F3-0EB9CE8CF54F

Q45184856-162E3A69-C019-4063-BCC3-6B3245853C36

Q45184856-19F2DF4D-2F82-4313-AA02-46400027AA79

Q45184856-2A2C0BDE-1A92-4005-A223-B26F87A7A7C2

Q45184856-2EE3539C-4313-480B-90D6-A508AEF089B4

Q45184856-30238C77-62F9-4663-8176-AEB081850F07

Q45184856-3711E9A1-4186-48FD-AC81-0F05970AEFAF

P304

Q45184856-A05A05D9-680B-4674-88E3-FF8C7B9E3643

P31

Q45184856-FFD6DC75-DA9C-4F0B-8A94-02BF8C36263C

P356

Q45184856-0E4BE641-D2CE-4E5B-BD4F-75BE982AADE6

P407

Q45184856-2FE4A2DD-3C06-45CE-862C-D6C410C4B277

P433

Q45184856-793B5BE6-B339-4431-A791-1CA3578C54B3

P478

Q45184856-17C7E861-7967-484F-A638-F7D52F90AAA1

P50

Q45184856-003795AA-3B4F-4FD6-AAD1-62DE83E4173F

Q45184856-0F232EC2-85D6-4DB4-A9D9-FFD01EF78FAF

Q45184856-75521C0F-5320-443B-A753-3F6E000CCA24

Q45184856-AB1BF982-5BD9-4108-BAAC-DE02956033D5

Q45184856-D2B3FA9C-9062-4989-B6E6-5C7D186B9E67

P577

Q45184856-689CCDD1-CB91-4ABA-98A6-F854FD565F30

P5875

Q45184856-68F36286-4AE1-4A06-9096-A1AC031C97AF

P698

Q45184856-CAB93703-E88D-4A59-87E4-4DFB48032493

P356

SCITRANSLMED.3000759

P1433

Science Translational Medicine

P1476

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

@en

P2093

Kazuo Sakurai

http://www.w3.org/2001/XMLSchema#string

Kouji Kobiyama

http://www.w3.org/2001/XMLSchema#string

Shizuo Akira

http://www.w3.org/2001/XMLSchema#string

Taiki Aoshi

http://www.w3.org/2001/XMLSchema#string

Takahiro Tougan

http://www.w3.org/2001/XMLSchema#string

Takeshi Tanimoto

http://www.w3.org/2001/XMLSchema#string

P2860

The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

Cryopyrin activates the inflammasome in response to toxins and ATP

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza?

P304

25ra24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000759

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Toshihiro Horii

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348170

http://www.w3.org/2001/XMLSchema#string

P698

20424013

http://www.w3.org/2001/XMLSchema#string